RhumbLine Advisers’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-744
| Closed | -$99K | – | 3156 |
|
|
2021
Q1 | $99K | Sell |
744
-90
| -11% | -$12K | ﹤0.01% | 2934 |
|
|
2020
Q4 | $133K | Buy |
834
+139
| +20% | +$22.2K | ﹤0.01% | 2929 |
|
|
2020
Q3 | $73K | Sell |
695
-150
| -18% | -$15.8K | ﹤0.01% | 2923 |
|
|
2020
Q2 | $102K | Buy |
845
+91
| +12% | +$11K | ﹤0.01% | 2963 |
|
|
2020
Q1 | $59K | Sell |
754
-8
| -1% | -$626 | ﹤0.01% | 2846 |
|
|
2019
Q4 | $224K | Buy |
762
+7
| +0.9% | +$2.06K | ﹤0.01% | 2714 |
|
|
2019
Q3 | $136K | Buy |
755
+20
| +3% | +$3.6K | ﹤0.01% | 2836 |
|
|
2019
Q2 | $293K | Buy |
735
+43
| +6% | +$17.1K | ﹤0.01% | 2620 |
|
|
2019
Q1 | $323K | Sell |
692
-22
| -3% | -$10.3K | ﹤0.01% | 2502 |
|
|
2018
Q4 | $343K | Buy |
714
+243
| +52% | +$117K | ﹤0.01% | 2471 |
|
|
2018
Q3 | $321K | Sell |
471
-23
| -5% | -$15.7K | ﹤0.01% | 2480 |
|
|
2018
Q2 | $337K | Buy |
+494
| New | +$337K | ﹤0.01% | 2475 |
|